6 REFERENCES

Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.Clin Cancer Res. 2004 Jul 15;10(14):4784-92

Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, Johnson AG, Reed MWR. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47: 612-617

Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DI. Prospective randomised controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc 2004; 59: 1-7

al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinoma. Int J Cancer 1993; 54: 213-219

Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006; 66(9): 4975-82

Attwood SE, Barlow AP, Norris TL, Watson A. Barrett's oesophagus: Effect of antireflux surgery on symptom control and development of complications. Br J Surg 1992; 79:1050-1053

Attwood SEA, Smyrk TC, DeMeester TR, Mirvish SS, Stein HJ, Hinder RA. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992;111:503-510

Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152: 135-144

Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulason TG, Rabinovich PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett's oesophagus. Nat Genet 1999; 22: 106-109

Bell AC, Felsenfeld. Methylation of a CTCF-dependent bundary controls imprinted expression of the Igf2 gene. Nature 2000: 405: 482-485

Bird AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Research 1980; 8:1499-1504

Bird A. The relationship of DNA methylation to cancer. Cancer Surv 1996; 28: 87-101

Bird A, Wolffe AP. Methylation-induced repression - belts, braces and chromatin. Cell 1999; 99: 451-454

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofocoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000; 343: 1520-1528

Brand DL, Ylvisaker JT, Gelfand M, Pope CE. Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery. N Engl J Med 1980; 302:844-848

Bremner RM, Cookes PF, DeMeester TR, Peters JH, Stein HJ. Concentration of refluxed acid and esophageal mucosal injury. Am J Surg 1992; 164: 522-526

Bright T, Watson DI, Tam W, Game PA, Astill D, Ackroyd R, Wijnhoven BPL, Devitt PG, Schoeman MN. Randomised trial of argon plasma coagulation versus endoscopic surveillance for Barrett's esophagus after antireflux surgery: Late results. Annals of Surgery 2007; 246: 1016-1020

British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus.www.bsg.org.uk 2005

Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG. Prognostic importance of promotor hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003; 9: 2912-2919

Bulay O, Mirvish S. Carcinogenesis in rat esophagus by intraperitoneal injection of different doses of methyl-n-amylnitrosamine. Cancer Research 1979: 39; 3644-3646

Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-1807

Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, Lutzke LS. The effect of selective cyclooxygenase inhibition in Barrett's esophagus epithelium: An in vitro study. J Natl Cancer Inst 2002; 94: 422-429

Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-1112

Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-859

Campomenosi P, Conio M, Bogliola M, Urbini S, Assereto P, Aprile A, Monti P, Aste H, Lapertosa G, Inga A, Abbondandolo A, Fronza G. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 1996; 5: 559-565

Castillo MH, Perkins E, Campbell JH, Doerr R, Hasset JM, Kandaswami C, Middleton E Jr. The effects of the bioflavonoids quercetin on squamous cell carcinoma of the head and neck. Am J Surg 1989; 158: 351-355

Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene. 2004; 23 :8841-8846.

Chandrasekharan NV, Dai H, Ross LT, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-2, a cyclooxygenase varient inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci U S A 2002; 99: 13926-13931

Chang EY, Morris CD, Seltman AK, O'Rourke RW, Chan BK, Hunter JG, Jobe BA. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus; a systematic review. Ann Surg 2007; 246(1): 11-21

Chen LQ, Hu CY, Gaboury L, Pera M, Ferraro P, Duranceau AC. Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann Surg 2001; 234(2):172-180

Chen X, Yang GY, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999; 20:1801-8

Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, Day NE. A case-control syudy of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000; 83: 127-132

Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane. Science 2002; 296: 539-542

Cheong E, Ivory K, Doleman J, Parker ML, Rhodes M, Johnson IT. Synthetic and naturally occurring COX-2 inhibitors supress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004; 25: 1945-1952

Clarke GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, Hinder RA, Bremner CG, DeMeester TR. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994; 129: 609-614

Clarke GWB, Smyrk TC, Mirvish SS, Anselmino M, Yamashita Y, Hinder RA, DeMeester TR, Birt DF. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: an experimental rat model. Annals of Surgical Oncology 1994; 1:252-261

Clemons NJ, McKoll KE, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 2007; 133(4): 1198-1209

Code of Practice for the Humane Killing of Animals under Schedule 1 to the Animals (Scientific Procedures) Act 1986. www.homeoffice.gov.uk

Coogan PF, Rosenburg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9: 119-123

Cooper BT, Barbezat GO. Treatment of Barrett's esophagus with H2 blockers. J Clin Gastroenterol 1987; 9: 139-141

Cooper BT, Barbezat GO. Barrett's oesophagus: A clinical study of 52 patients. Q J Med 1987; 62:97-108

Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23: 727-733

Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20mg daily for up to 6 years in Barrett's esophagus. Aliment Pharmacol Ther 1998; 12: 893-897

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martinson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichmann LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow up of a prospective randomised trial (RTOG 85-01; Radiation Therapy Oncology Group). Jama 1999; 281: 1623-1627

Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390-2394

Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56

Csendes A, Braghetto I, Burdiles P, Puente G, Korn O, Diaz JC, Maluenda F. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 1998; 123(6):645-657

DeMeester TR, Attwood SE, Smyrk TC, Therkildsen DH, Hinder RA. Surgical therapy in Barrett's esophagus. Ann Surg 1990; 212(4):528-540

Deschner EE, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 1991; 12: 1193-1196

Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053

Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem. 2001; 276: 20809

Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's oesophagus: a prospective study of 170 patients followed 4.8years. Am J Gastroenterol 1997; 92: 212-215

Druckrey HD, Preussmann R, Ivankovic S, Schmahl D. Organotrope carcinogene wirkungen bei 65 verschiedenen N-nitrosoverbindungen an BD-ratten. Z Krebsforsch 1967; 69: 103-201

DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1963-1973

DuBois RN, Awad J, Morrow J, Roberts LJ 2nd, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor alpha and phorbol ester. J Clin Invest 1994; 93: 493-498

Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW. Epigenetic

patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61: 3410-3418

Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-5413

Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, Henrich R, Vieth M, Muller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high grade dysplasia in Barrett's esophagus. Gastroenterol 2000; 118: 670-677

El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-1883

Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West B, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 2003; 95: 1404-1413

Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16ink4a, RARβ, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005; 11(19); 7033-7041

Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996; 7: 322-327

Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102

Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-) epigallocatechin 3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570

Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, Bremner CG, Hagen JA, DeMeester TR. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. Journal of Gastrointestinal Surgery 1998; 2:260-268

Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's oesophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-8.

Formica JV, Regelson W. Review of the biology of quercetin and related bioflavanoids. Food Chem Toxicol 1995; 33: 1061-1080

Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-1119

Gali HU, Perchellet EM, Perchellet JP. Inhibition of tumour promotor-induced ornithine decarboxylase activity by tannic acid and other polyphenols in mouse epidermis in vivo. Cancer Res. 1991; 51: 2820-2825

Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant (Barrett's) tissue. J Natl Cancer Inst 1999; 91: 2087-95

Gao YT, McLaughlin JK, Blot WJ, Ji BT, Dai Q, Fraumini JF Jr. Reduced risk of esophageal cancer associated with green tea consumption. J. Natl Cancer Inst 1994; 86: 855-858

Gee JM, Hara H, Johnson IT. Suppression of intestinal crypt cell proliferation and aberrant crypt foci by dietary quercetin in rats. Nutrition and Cancer 2002; 43: 193-201

Giaretti W. Aneuploidy mechanisms in human colorectal preneoplastic lesions and Barrett's oesophagus. Is there a role for K-ras and p53 mutations? Anal Cell Pathol 1997; 15: 99-117

Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, Newmark HL, Yang CS. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997; 18:2265-2270

Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, Coto E. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997; 50: 212-217

Gonzalez-Perez A, Rodriguez LAG, Lopez-Riduara R. Effects of non-steroidal anti-inflammatory drugs on cancer sires other than the colon and rectum: meta-analysis. BMC Cancer 2003; 3: 28

Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MWL, Shepherd NA, Wilkinson SP. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-628

Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske FF. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 1969; 56: 223-230

Halliwell B, Zhao K, Whiteman M. The gastrointestinal tract: a major site of antioxidant action. Free Radic Res 2000; 33: 819-830

Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107: 1012-1018

Hanas JS, Lerner MR, Lightfoot SA, Raczkowski C, Kastens DJ, Brackett DJ, Postier RG. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer 1999; 86: 756-763

Hardwick JCH, van Santen M, van den Brink GR, van Deventer SJH, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells. Involvement of Rac 1. Carcinogenesis 2004; 25: 1293-1298

Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. c-erbB-2 overexpression in the dysplasia/carcinoma sequence in Barrett's oesophagus. J Clin Pathol 1995; 48: 129-132

Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405:486-489

Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1981; 26: 65-72

Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001; 281: F1-F11

Helsingen N. Oesophageal lesions following total gastrectomy in rats I. Development and nature. Acta Chirurg Scandinav 1960; 118: 202-216

Helsingen N. Oesophageal lesions following total gastrectomy in rats II. Development of oesophagitis in relation to type of reconstruction. Acta Chirurg Scandinav 1960; 119: 230-245

Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretions in clinical esophagitis. Gastroenterology 1991; 101: 1149-1158

Hollman PCH, Arts ICW. Flavonols, flavones and flavanols – nature, occurrence and dietary burden. J. Sci. Food. Agric 2000; 80: 1081-1093

Iftikhar SY, Ledingham S, Steele RJC, Evans DF, Lendrum K, Atkinson M, Hardcastle JD Bile reflux in columnar lined Barrett's oesophagus. Ann R Coll Surg Engl 1993; 75: 411-416

Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and camp response element. J Biol Chem 1995; 270: 965-71

Jang TJ, Min SK, Bae JD, Jung KH, Lee JI, Kim JR, Ahn WS. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dypslasia and Barret's metaplasia induced by duodenal contents reflux. Gut 2004; 53:27-33

Jankowski JA. Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus. Gut 1993; 34: 1649-1650

Jankowski JA, Harrison RF, Perry I, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2085

Jankowski J, Hopwood D, Wormsley KG. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's esophagus and esophageal adenocarcinoma. Scand J Gastroenterol 1992; 27: 147-154

Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965-973

Jenkins GJS, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002; 89: 824-837

Jenkins GJ, D'Souza FR, Suzen SH, Eltahir ZS, James SA, Parry JM, Griffiths PA, Baxter JN. Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis 2007; 28(1): 136-142

Johnson DA, Cruess DF, Cotelingam JD, Gurney MS. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-124

Johnsson F, Joelsson B, Floren CH, Nilsson A. Bile salts in the esophagus of patients with esophagitis. Scand J Gastroenterol 1988; 23: 712-16

Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-9054

Kanadaswami C, Lee LT, Lee PPH, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumour activities of flavanoids. In vivo 2005; 19: 895-910

Kataoka N, Young SR, Wang Z, Jakub JW. FISH studies of c-myc, cyclin D1, p53 and chromosomes 8,11 and 17 centromeres in Barrett's dysplasia and adenocarcinoma of the esophagus. Am J Hum Genet 1999; 65: A132 (Abstract)

Kaur BS, Khamnehei N, Iravani M, Namburu SS. Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-67

Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93(4):536-541

Kiliruk LB, Merendino KA. Comparative sensitivity of mucosa of various segments of alimentary tract in dog to acid-peptic action. Surgery 1954; 35: 547-556

Kim DO, Lee KW, Lee HJ, Lee CY. Vitamin C equivalent antioxidant capacity (VCEAC) of phenolic phytochemicals. J. Agri. Food. Chem 2002; 50: 3713-3717

Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A; Long-Term Study Group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118(4):661-669

Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Luckers A, Dekkers CP, Havu N, Meuwissen SG. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121(3):161-167

Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 1997; 112: 348-356

Lagorce-Pages C, Paraf F, Dubois S, Belghiti J, Flejou JF. Expression of CD44 in premalignant and malignant Barrett's oesophagus. Histopathology 1998; 32: 7-14

Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2(3): 149-156

Langergren J, Bergstrom R, Lingren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831

Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642-1646

Levrat M, Lambert R, Kirshbaum G. Esophagitis produced by reflux of duodenal contents in rats. Am J Dig Dis 1962; 7:564-573

Li Z, Shimada Y, Kawabe A, Sato F, Maeda M, Komoto I, Hong T, Ding F, Kanganoi J, Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001; 22: 547-551

Lin L, Prescott MS, Zhu Z, Singh P, Chun SY, Kuick RD, Hanash SM, Orringer MB, Glover TW, Beer DG. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res 2000; 60: 7021-7027

Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Over expression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-18569

Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Risk factors associated with the symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-649

Formatted: Indent: Left: 2 cm

Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999; 94:80-85

Luostarinen ME, Mattila JJ, Auvinen OL, Matikainen MJ, Isolauri JO. Histological improvement of oesophagitis after Nissen fundoplication. Ann Med 1998; 30:547-552

Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Lamm M, Blomqvist A, Hatlebakk JG, Janatuinen E, Levander K, Nystrom P, Wiklund I. Long-term management of gastro-oesophageal reflux disease with omeprazole or open anti-reflux surgery: results of a prospective randomised clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000; 12(8):879-887

Ma L, Feugang JM, Konarski P, Wang J, Lu J, Fu S, Ma B, Tian B, Zou C, Wang Z. Growth inhibitory effects of quercetin on bladder cancer cell. Front Biosci 2006; 11: 2275-2285

Malesci A, Savarino V, Zentilin P, Belicchi M, Mela G, Lapertosa G, Bocchia P, Ronchi G, Franceschi M. Partial regression of Barrett's esophagus by long-term therapy with high dose omeprazole. Gastrointest Endosc 1996; 44: 700-705

McDonald ML, Trastek VF, Allen Msarrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111:1135-1138

Melo LL, Kruel CDP, Kliemann LM, Cavazzola LT, da Luz Boeno R, Silber PC, Grossi RS. Influence of surgically induced gastric and gastroduodenal content reflux on esophageal carcinogenesis – experimental model in Wistar female rats. Diseases of the Esophagus 1999; 12:106-115

Menke-Pluymers MBE, Hop WCJ, Dees J, Van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar lined (Barrett's) esophagus. The Rotterdam Esophageal Tumour Study Group. Cancer 1993; 72:1155-1158

Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett's ooesophagus. Gut 1992;33:1454-8.

Miller CT, Moy JR, Lin L, Schipper M, Normolle D, Brenner DE, Iannettoni MD, Orringer MB, Beer DG. Gene amplification in esophageal adenocarcinomas and Barrett's with high grade dysplasia. Clin Cancer Res 2003; 9: 4819-4825

Mirvish SS. Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of oesophageal adenocarcinoma. Cancer Lett 1997;117:161-74.

Mittal A, Piyathilake C, Hara Y, Katiyar SK. Exceptionally high protection of photocarcinogenesis by topical application of (-) epigallocatechin 3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 2003; 5: 555-565

Miwa K, Sahara H, Segewa M, Kinami S, Sato T, Miyazaki I, Hattori T. Reflux of duodenal or gastroduodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996; 67:269-274

Molnar J, Beladi I, Domonkos K, Foldeak S, Boda K, Veckenstedt A. Antitumour activity of flavonoids on NK/Ly ascites tumour cells. Neoplasm 1981; 28: 11-18

Morales AI, Vicente-Sanchez c, Jerkic M, Santiago JM, Sanchez-Gonzalez PD, Perez-Barriocanal F, Lopez-Novoa JM. Effect of quercetin on metallothionein, nitric oxide synthases and cyclooxygenase-2 expression on experimental

chronic cadmium nephrotoxicity in rats. Toxicol Appl Pharmacol 2006; 210: 128-35

Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-659

Mork H, Al-Taie O, Berlin F, Kraus MR, Scheurlen. High recurrence rate of Barrett's epithelium during long term follow up after argon plasma coagulation. Scand J Gastroent 2007; 42: 23-27

Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-996

Morris CD, Byrne JP, Armstrong GRA, Attwood SEA. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88: 1357-1362

MRC Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised trial. Lancet 2002; 359: 1727-1733

Mutoh M, Takahashi M, Fukuda K, Matsushima-Hibiya Y, Mutoh H, Sigimura T, Wakakayashi K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis. 2000; 21: 959-63

Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999; 44: 598-602

Neumann C, Iqbal T, Cooper B. Long term continuous omeprazole treatment of patients with Barrett's esophagus. Aliment Pharmacol Ther 1995; 9: 451-454

Oberg S, Lord RV, Peters JH, Chandrasoma P, Theisen J, Hagen JA, DeMeester SR, Bremner CG, DeMeester TR. Is adenocarcinoma following esophagoduodenostomy without a carcinogen in the rat reflux-induced. Journal of Surgical Research 2000; 91:111-117

Oberg S, Peters JH, DeMeester TR, Lord RV, Johanson J, DeMeester SR, Hagen JA. Determinants of intestinal metaplasia within the columnar-lined esophagus. Arch Surg 2000; 135: 651-655

Oberg S, Ritter MP, Crookes PF, Fein M, Mason RJ, Gadensytatter M, Brenner CG, Peters JH, DeMeester TR. Gastroesophageal reflux disease and mucosal injury with emphasis on short segment Barrett's esophagus and duodenogastroesophageal reflux. J Gastrointest Surg 1998; 2: 547-553

Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55: 1000-1006

Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, Liron R, Aguilar J. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996: 83(2):274-278

Orlando RC, Powell DW, Carney CN. Pathophysiology of acute acid injury in rabit esophageal epithelium. J Clin Invest 1981; 68: 286-293

Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Traskos JM, Evans JF, Taketo MM. Supression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809

Overholt BF, Lightdale CJ, Wang, KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MGA, Depot M. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international partially blinded, randomised phase III trial. Gastrointestinal Endosc 2005; 62: 488-507

Overholt BF, Wang KK, Burdick S, Lightdale CJ, Kimmey M, Nava HR, Sivak MV, Jr, Nishioka N, Barr H, Marcon N, Pedrosa M, Bronner MP, Grace MG, Depot M. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointestinal Endosc 2007; 66: 460-468

Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989; 34:1336-1339

Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohata T, Koichi M. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005; 26: 565-570

Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002; 8: 289-293

Patterson RE, Neuhouser ML, White E, Hunt JR, Kristal AR. Cancer-related behaviour of vitamin supplement users. Cancer Epidemiol Biomarkers Prev 1998; 7: 79-81

Patti MG, Arcerito M, Feo CV, Worth S, De Pinto M, Gibbs VC, Gantert W, Tyrrell D, Ferrell LF, Way LW. Barrett's esophagus: a surgical disease. J Gastrointest Surg 1999; 3(4):397-403

Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumour

Pera M, Cardesa A, Bombi JA, Ernst H, Pera C, Mohr U. Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine. Cancer Research 1989; 49: 6803-6808

Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumours. Carcinogenesis 2004; 25(10): 1917-1923

Peters FTM, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CBHW, Kleibeuker. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-494

Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumour cells and role of prostaglandins. Proc. Natl. Acad. Sci. U.S.A. 1975; 72: 1848

Pritchard KA, O'Banion MK, Miano JM, Vlasic N, Bhatia UG, Young DA, Stemerman MB. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem 1994; 269: 8504-8509

Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680

Raizis AM, Schmitt F, Jost JP. A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. Anal Biochem 1995;226:161-6

Ranka S, Gee JM, Johnson IT, Skinner J, Hart AR, Rhodes M. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter relaxing drugs and oesophageal cancer. A case-control study. Digestion 2006; 74(2): 109-15

Redo SF, Barnes WA de la Sierra AO. Perfusion of the canine esophagus with secretions of the upper gastrointestinal tract. Ann Surg 1959; 149: 556-564

Riddell RH. The genesis of Barrett esophagus. Arch Pathol Lab Med 2005; 129: 164-169

Rioux-Leclercq N, Turlin B, Sutherland F, Heresbach N, Launois B, Campion JP, Ramee MP. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus. Oncol Rep 1999; 6: 877-882

Rodriguez RJ, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem Toxicol 2001; 39: 437-445

Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC; Australian Cancer Study. Cancer Epidemiol Biomarkers Prev 2008; 17(5): 1169-78

Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard CJ, Kingsnorth AN. Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg 1995; 82(6): 806-810

Sampliner RE. Effect of up to 3 years of high-dose lanzoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89:1844-1848

Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990; 35: 93-96

Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. Flavonol and flavone intakes in US health professionals. J. Am. Diet. Assoc 2002; 102: 1414-1420

Saretzki G, Von Zglinicki T. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci 2002; 959: 24-29

Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006; 106: 483-493

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wnag S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's associated neoplastic progression and predicts progression risk. Oncogene 2005; 24: 4138-4148

Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. N Engl J Med 2009; 360(22): 2277-88

Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92(11):2012-2016

Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-585

Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000; 46(1):9-13

Sharp L, Chilvers CE, Cheng KK, McKinney PA, Logan RF, Cook-Mozaffari P, Ahmed A, Day NE. Risk factors for squamous cell carcinoma of the oesophagus in women. A case-control study. Br J Cancer 2001; 85: 1667-1670

Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-496

Siglin JC, Khare L, Stoner GD. Evaluation of dose and treatment duration on the esophageal tumorigenicity of N-nitrosomethylbenzylamine in rats. Carcinogenesis 1995; 16: 259-265

Silva MM, Santos MR, Caroco G, Rocha R, Justino G, Mira L. Structure-antioxidant activity relationships of flavonoids. Free Radic Res 2002; 36

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowitz JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study – a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255

Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198(4):554-565

Soulinna EM, Buchsbaum RN, Racker E. The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res 1975; 35: 1865-1872

Soslow RA, Altorki NK, Yang GY, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999; 12: 580-586

Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 supresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Research 2000; 60: 5767-5772

Spahos T, Hindmarsh A, Cameron E, Tighe MR, Igali L, Pearson D, Rhodes M, Lewis MPN. Endoscopy waiting times and the impact of the two week wait scheme on diagnosis and outcome of upper gastrointestinal cancer. Postgrad Med J 2005; 81: 728-730

Spechler SJ, Goyal RK,. Barrett's esophagus. N Engl J Med 1986; 315: 362-371

~~Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680~~

Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontaq S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomised controlled trial. JAMA 2001; 285(18):2331-2338

Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM. Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology 1984; 87: 927-933

Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001; 15(4):519-524

Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, Lynch JP, Rustigi AK. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PloS ONE 2008; 3(10): e3534. Epub 2008 Oct 27

Starnes VA, Adkins RB, Ballinger JF, Sawyers JL. Barrett's esophagus. A surgical entity. Arch Surg 1984; 119:563-567

Su Y, Chen X, Klein M, Fang M, Wang S, Yang CS, Goyal RK. Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett's esophagus. Laboratory Investigation 2004; 84:753-765

Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 4424-4429

Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000; 9: 185-191

Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol 1995; 90: 1808-1813

Tao L, Wang W, Kramer PM, Lubet RA, Steele VE, Pereira MA. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol Carcinogen 2004; 39: 79-84

Terry P, Lagergren J, Hansen, Wolk A, Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. European Journal of Cancer Prevention 2001; 10: 365-369

Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327

Tselepis C, Perry I, Jankowski J. Barrett's esophagus: disregulation of cell cycling and intracellular adhesion in the metaplasia-dysplasia-adenocarcinoma sequence. Digestion 2000; 61: 1-5

Formatted: Indent: Left: 2 cm

Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501

Tsujii M, Kawano S, DuBois RN. Cyclooxygenase 2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 3336

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716

Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomised trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313

Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-1199

Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk? Gut 1989; 30: 14-18

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature 1971; 231: 232-251

Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005; 6(12): 945-52.

Vinegar R, Truax JF, Self JL. Quantitative comparison of the analgesic and anti-inflammatory activities of aspirin, phenacetin and acetaminophen in rodents. Eur J Pharm 1976;37:23-30

Volate SR, Davenport DM, Muga SJ, Wargovich MJ. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng, rutin). Carcinogenesis 2005; 26: 1450-1456

Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles and the catagorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999; 107: 11S-17S

Walsh TN, Noonan N, Hollywood A, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467

Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18:790-804

Wesdorp IC, Bartelsman J, Schipper ME, Tytgat GN. Effect of long-term treatment with cimetidine and antacids in Barrett's oesophagus. Gut 1981; 22:724-727

Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94:3413-3419

Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar lined (Barrett's) oesophagus with ~~omeprazole 4057 with~~ omeprazole 40mg daily: results of 5 years continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-1209

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49(4):537-541

Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58:2929-2934

Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-124

Wu DL, Sui FY, Jiang XM, Jiang XH. Methylation in esophageal carcinogenesis. World J Gastroenterol 2006; 12: 6933-6940

Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett's esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998; 153: 287-94

Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux disease and after antireflux surgery. Gastroenterology 2001; 121: 1286-1293

Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus 2003; 16: 193-198

Younes M, Schwartz MR, Finnie D, Younes A. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 1999; 30: 1309-1313

Zimmermann KC, Sarbia M, Weber AA, Brochard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204

7 APPENDIX

7.1 RAT DIETS

7.1.1 Semi-Synthetic and Experimental Rat Diets

Ingredients	g/Kg		
	Semi-synthetic chow	Aspirin	Quercetin
Vitamin mixture	20	20	20
Mineral mixture	40	40	40
DL-methionine	2	2	2
Cellulose	100	100	100
Casein	200	200	200
Starch	260	259.5	258.75
Sucrose	298	298	298
Corn oil	80	80	80
Drug		0.5	1.25
Total	1000	1000	1000

7.1.2 Components of the Mineral Mix

Ingredients	g/Kg
Calcium Hydrogen Orthophosphate (CaHPO4)	322.8
Di-Sodium Hydrogen Orthophosphate (Na2HPO4)	185
Calcium Carbonate (CaCO3)	205
Potassium Chloride (KCl)	175.5
Magnesium Sulphate (dried) (MgSO4)	100

Trace Element Pre Mix (added to Mineral Mix)

Ingredients	g/Kg
Zinc Carbonate (ZnCO3)	2.5
Ferrous Sulphate (FeSO4)	3.6
Cupric Sulphate (CuSO4)	0.575
Potassium Iodate (KIO3)	0.025
Manganous Sulphate (MnSO4)	4.5

7.1.3 Components of the Vitamin Mix

Ingredients	g/Kg
Nicotinic Acid	3
B12 in Mannitol	2.5
D-Pantothenic Acid	2
Thiamine Hydrochloride (B1)	0.5
Riboflavin (B2)	0.5
Pyridoxine	0.5
Folic Acid	0.5
D-Biotin	0.05
Vitamin K1	0.1
Rovi Mix E50	7.5
Rovi Mix A500	1.25
Rovi Mix D3500	0.75
Choline Bitartrate	90
Starch	890.85